siRNA genome screening approaches to therapeutic drug repositioning

Pharmaceuticals

Volumn 6, Issue 2, 2013, Pages 124-160

  Perwitasari, Olivia ^a   Bakre, Abhijeet ^a   Mark Tompkins, S ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiviral; Bacteria; Genome; Host genes; HTS; miRNA; Pathogen; Pathway; Reposition; Repurpose; RNAi; siRNA; Therapeutic; Virus

Indexed keywords

AMFEBUTAMONE; AMPHOTERICIN; ARSENIC; ASTEMIZOLE; AURANOFIN; CEFTRIAXONE; CLOSANTEL; COTRIMOXAZOLE; DAPOXETINE; DAPSONE; DIGOXIN; EFLORNITHINE; FOSMIDOMYCIN; FUMAGILLIN; HARMINE; ITRACONAZOLE; MEPACRINE; MILTEFOSINE; MYCOPHENOLIC ACID; NITROXOLINE; PAFURAMIDINE; PAROMOMYCIN; PENTAMIDINE; RALOXIFENE; RETINOIC ACID; RILUZOLE; SMALL INTERFERING RNA; SUTEZOLID; THALIDOMIDE;

3' UNTRANSLATED REGION; ACNE; AEROMONAS PUNCTATA; AFRICAN TRYPANOSOMIASIS; AMEBIASIS; AMYOTROPHIC LATERAL SCLEROSIS; BRUCELLA; CANDIDA ALBICANS; CELL ACTIVATION; CELL DIFFERENTIATION; COXSACKIE VIRUS; CREUTZFELDT JAKOB DISEASE; CRYPTOCOCCUS NEOFORMANS; DENGUE VIRUS; DEPRESSION; DROSOPHILA; EBOLA VIRUS; ELECTROPORATION; ERYTHEMA; EXPRESSION VECTOR; FRANCISELLA TULARENSIS; GENE CONTROL; GENE SILENCING; GENETIC SCREENING; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLUENZA VIRUS; LEISHMANIASIS; LISTERIA MONOCYTOGENES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NONHUMAN; ONCHOCERCIASIS; PARAINFLUENZA VIRUS; PLASMODIUM FALCIPARUM; POLIOMYELITIS VIRUS; POLYADENYLATION; PREMATURE EJACULATION; PROMYELOCYTIC LEUKEMIA; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; RNA INTERFERENCE; SALMONELLA TYPHIMURIUM; SKIN LEISHMANIASIS; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; TUBERCULOSIS; URINARY TRACT INFECTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VISCERAL LEISHMANIASIS; WART VIRUS; WEST NILE FLAVIVIRUS;

EID: 84873112511     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6020124     Document Type: Review

References (169)

1. Mayr, L.M.; Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 2009, 9, 580-588.
2. Waszkowycz, B. Towards improving compound selection in structure-based virtual screening. Drug Discov. Today 2008, 13, 219-226.
3. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 2006, 5, 993-996.
4. Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004, 3, 673-683.
5. Drews, J. What's in a number? Nat. Rev. Drug Discov. 2006, 5, 975-975.
6. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
7. Carthew, R.W.; Sontheimer, E.J. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642-655.
8. Liu, C.; Bai, B.; Skogerbo, G.; Cai, L.; Deng, W.; Zhang, Y.; Bu, D.; Zhao, Y.; Chen, R. NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res. 2005, 33, D112-115.
9. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854.
10. Eddy, S.R. Non-coding RNA genes and the modern RNA world. Nat. Rev. Genet. 2001, 2, 919-929.
11. Reinhart, B.J.; Slack, F.J.; Basson, M.; Pasquinelli, A.E.; Bettinger, J.C.; Rougvie, A.E.; Horvitz, H.R.; Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403, 901-906.
12. Mo, Y.-Y. MicroRNA regulatory networks and human disease. Cell. Mol. Life Sci. 2012, 69, 3529-3531.
13. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Sutton, G.G.; Smith, H.O.; Yandell, M.; Evans, C.A.; Holt, R.A. et al. The sequence of the human genome. Science 2001, 291, 1304-1351.
14. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21, 635-637.
15. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W.S.; Khvorova, A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22, 326-330.
16. Jackson, A.L.; Burchard, J.; Schelter, J.; Chau, B.N.; Cleary, M.; Lim, L.; Linsley, P.S. Widespread siRNA off-target transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12, 1179-1187.
17. Lai, E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative posttranscriptional regulation. Nat. Genet. 2002, 30, 363-364.
18. Li, L.; Xu, J.; Yang, D.; Tan, X.; Wang, H. Computational approaches for microRNA studies: a review. Mamm. Genome 2010, 21, 1-12.
19. Licatalosi, D.D.; Mele, A.; Fak, J.J.; Ule, J.; Kayikci, M.; Chi, S.W.; Clark, T.A.; Schweitzer, A.C.; Blume, J.E.; Wang, X. et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 2008, 456, 464-469.
20. Hafner, M.; Landthaler, M.; Burger, L.; Khorshid, M.; Hausser, J.; Berninger, P.; Rothballer, A.; Ascano, M.; Jungkamp, A.C.; Munschauer, M. et al. PAR-CliP--a method to identify transcriptome-wide the binding sites of RNA binding proteins. J. Vis. Exp. 2010, 41, pii: 2034.
21. Aza-Blanc, P.; Cooper, C.L.; Wagner, K.; Batalov, S.; Deveraux, Q.L.; Cooke, M.P. Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening. Mol. Cell 2003, 12, 627-637.
22. Berns, K.; Hijmans, E.M.; Mullenders, J.; Brummelkamp, T.R.; Velds, A.; Heimerikx, M.; Kerkhoven, R.M.; Madiredjo, M.; Nijkamp, W.; Weigelt, B. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428, 431-437.
23. Paddison, P.J.; Silva, J.M.; Conklin, D.S.; Schlabach, M.; Li, M.; Aruleba, S.; Balija, V.; O'Shaughnessy, A.; Gnoj, L.; Scobie, K. et al. A resource for large-scale RNA-interference- based screens in mammals. Nature 2004, 428, 427-431.
24. Kittler, R.; Putz, G.; Pelletier, L.; Poser, I.; Heninger, A.-K.; Drechsel, D.; Fischer, S.; Konstantinova, I.; Habermann, B.; Grabner, H. et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004, 432, 1036-1040.
25. Sachse, C.; Krausz, E.; Krönke, A.; Hannus, M.; Walsh, A.; Grabner, A.; Ovcharenko, D.; Dorris, D.; Trudel, C.; Sönnichsen, B. et al. High-Throughput RNA Interference Strategies for Target Discovery and Validation by Using Synthetic Short Interfering RNAs: Functional Genomics Investigations of Biological Pathways. Methods Enzymol. 2005, 392, 242-277.
26. Whitehurst, A.W.; Bodemann, B.O.; Cardenas, J.; Ferguson, D.; Girard, L.; Peyton, M.; Minna, J.D.; Michnoff, C.; Hao, W.; Roth, M.G. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446, 815-819.
27. Simpson, K.J.; Davis, G.M.; Boag, P.R. Comparative high-throughput RNAi screening methodologies in C. elegans and mammalian cells. N. Biotechnol. 2012, 29, 459-470.
28. Mohr, S.; Bakal, C.; Perrimon, N. Genomic screening with RNAi: results and challenges. Annu. Rev. Biochem. 2010, 79, 37-64.
29. Mohr, S.E.; Perrimon, N. RNAi screening: new approaches, understandings, and organisms. Wiley Interdiscip. Rev. RNA 2012, 3, 145-158.
30. Russ, A.P.; Lampel, S. The druggable genome: an update. Drug Discov. Today 2005, 10, 1607-1610.
31. Conrad, C.; Gerlich, D.W. Automated microscopy for high-content RNAi screening. J. Cell Biol. 2010, 188, 453-461.
32. Ghildiyal, M.; Zamore, P.D. Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 2009, 10, 94-108.
33. Griffiths-Jones, S.; Saini, H.K.; van Dongen, S.; Enright, A.J. miRBase: tools for microRNA enomics. Nucleic Acids Res. 2008, 36, D154-D158.
34. Friedman, R.C.; Farh, K.K.-H.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 2009, 19, 92-105.
35. Leung, R.K.; Whittaker, P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 2005, 107, 222-239.
36. Meliopoulos, V.A.; Andersen, L.E.; Birrer, K.F.; Simpson, K.J.; Lowenthal, J.W.; Bean, A.G.; Stambas, J.; Stewart, C.R.; Tompkins, S.M.; van Beusechem, V.W. et al. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J 2012, 26, 1372-1386.
37. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411, 494-498.
38. Sakurai, K.; Chomchan, P.; Rossi, J.J. Silencing of gene expression in cultured cells using small interfering RNAs. Curr. Protoc. Cell Biol. 2010, Chapter 27, Unit 27 21 21-28.
39. Gopalakrishnan, B.; Wolff, J. siRNA and DNA transfer to cultured cells. Methods Mol. Biol. 2009, 480, 31-52.
40. Felgner, P.L.; Gadek, T.R.; Holm, M.; Roman, R.; Chan, H.W.; Wenz, M.; Northrop, J.P.; Ringold, G.M.; Danielsen, M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 1987, 84, 7413-7417.
41. Recillas-Targa, F. Multiple strategies for gene transfer, expression, knockdown, and chromatin influence in mammalian cell lines and transgenic animals. Mol. Biotechnol. 2006, 34, 337-354.
42. Bukrinsky, M.I.; Sharova, N.; Dempsey, M.P.; Stanwick, T.L.; Bukrinskaya, A.G.; Haggerty, S.; Stevenson, M. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA 1992, 89, 6580-6584.
43. Manjunath, N.; Wu, H.; Subramanya, S.; Shankar, P. Lentiviral delivery of short hairpin RNAs. Adv. Drug. Deliv. Rev. 2009, 61, 732-745.
44. Sliva, K.; Schnierle, B.S. Selective gene silencing by viral delivery of short hairpin RNA. Virol. J. 2010, 7, 248.
45. Lewis, P.; Hensel, M.; Emerman, M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992, 11, 3053-3058.
46. Lewis, P.F.; Emerman, M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 1994, 68, 510-516.
47. Miller, D.G.; Adam, M.A.; Miller, A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 1990, 10, 4239-4242.
48. Mitani, K.; Kubo, S. Adenovirus as an integrating vector. Curr. Gene Ther. 2002, 2, 135-144.
49. Grimm, D.; Pandey, K.; Kay, M.A. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. 2005, 392, 381-405.
50. Ewert, K.K.; Zidovska, A.; Ahmad, A.; Bouxsein, N.F.; Evans, H.M.; McAllister, C.S.; Samuel, C.E.; Safinya, C.R. Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top. Curr. Chem. 2010, 296, 191-226.
51. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
52. Kim, V.N.; Han, J.; Siomi, M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10, 126-139.
53. Saxena, S.; Jonsson, Z.O.; Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 2003, 278, 44312-44319.
54. Theis, M.; Buchholz, F. MISSION esiRNA for RNAi Screening in Mammalian Cells. J. Vis. Exp. 2010, 39, pii: 2008.
55. Reynolds, A.; Anderson, E.M.; Vermeulen, A.; Fedorov, Y.; Robinson, K.; Leake, D.; Karpilow, J.; Marshall, W.S.; Khvorova, A. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006, 12, 988-993.
56. Kim, D.H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 2004, 22, 321-325.
57. de Veer, M.J.; Sledz, C.A.; Williams, B.R.G. Detection of foreign RNA: Implications for RNAi. Immunol Cell Biol 2005, 83, 224-228.
58. Bartlett, D.W.; Davis, M.E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 2007, 97, 909-921.
59. Eberle, F.; Giessler, K.; Deck, C.; Heeg, K.; Peter, M.; Richert, C.; Dalpke, A.H. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol. 2008, 180, 3229-3237.
60. Robbins, M.; Judge, A.; Liang, L.; McClintock, K.; Yaworski, E.; MacLachlan, I. 2'-O-methyl- modified RNAs act as TLR7 antagonists. Mol. Ther. 2007, 15, 1663-1669.
61. Saleh, M.-C.; van Rij, R.P.; Hekele, A.; Gillis, A.; Foley, E.; O'Farrell, P.H.; Andino, R. The ndocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat. Cell Biol. 2006, 8, 793-802.
62. Dieudonne, A.; Torres, D.; Blanchard, S.; Taront, S.; Jeannin, P.; Delneste, Y.; Pichavant, M.; Trottein, F.; Gosset, P. Scavenger receptors in human airway epithelial cells: role in response to double-stranded RNA. PLoS One 2012, 7, e41952.
63. Takahashi, Y.; Nishikawa, M.; Takakura, Y. Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv. Drug Deliv. Rev. 2009, 61, 760-766.
64. Chiu, Y.L.; Rana, T.M. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 2002, 10, 549-561.
65. Singh, S.; Narang, A.S.; Mahato, R.I. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 2011, 28, 2996-3015.
66. Goff, S.P. Retroviridae: The Retroviruses and Their Replication. In Fields Virology; Knipe, D. M.; Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2001; Vol. 2, pp. 1871-1940.
67. Gupta, S.; Schoer, R.A.; Egan, J.E.; Hannon, G.J.; Mittal, V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 2004, 101, 1927-1932.
68. Agaisse, H.; Burrack, L.S.; Philips, J.A.; Rubin, E.J.; Perrimon, N.; Higgins, D.E. Genome-wide RNAi screen for host factors required for intracellular bacterial infection. Science 2005, 309, 1248-1251.
69. Chong, R.; Squires, R.; Swiss, R.; Agaisse, H. RNAi screen reveals host cell kinases specifically involved in Listeria monocytogenes spread from cell to cell. PLoS One 2011, 6, e23399.
70. Philips, J.A.; Rubin, E.J.; Perrimon, N. Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science 2005, 309, 1251-1253.
71. Koo, I.C.; Ohol, Y.M.; Wu, P.; Morisaki, J.H.; Cox, J.S.; Brown, E.J. Role for lysosomal enzyme beta-hexosaminidase in the control of mycobacteria infection. Proc. Natl. Acad. Sci. USA 2008, 105, 710-715.
72. Jayaswal, S.; Kamal, M.A.; Dua, R.; Gupta, S.; Majumdar, T.; Das, G.; Kumar, D.; Rao, K.V. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog. 2010, 6, e1000839.
73. Kumar, D.; Nath, L.; Kamal, M.A.; Varshney, A.; Jain, A.; Singh, S.; Rao, K.V. Genome-wide nalysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 2010, 140, 731-743.
74. Derre, I.; Pypaert, M.; Dautry-Varsat, A.; Agaisse, H. RNAi screen in Drosophila cells reveals the involvement of the Tom complex in Chlamydia infection. PLoS Pathog. 2007, 3, 1446-1458.
75. Elwell, C.A.; Ceesay, A.; Kim, J.H.; Kalman, D.; Engel, J.N. RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog. 2008, 4, e1000021.
76. Gurumurthy, R.K.; Maurer, A.P.; Machuy, N.; Hess, S.; Pleissner, K.P.; Schuchhardt, J.; Rudel, T.; Meyer, T.F. A loss-of-function screen reveals ras-and raf-independent mekerk signaling during chlamydia trachomatis infection. Sci. Signal. 2010, 3, ra21.
77. Garvis, S.; Munder, A.; Ball, G.; de Bentzmann, S.; Wiehlmann, L.; Ewbank, J.J.; Tummler, B.; Filloux, A. Caenorhabditis elegans semi-automated liquid screen reveals a specialized role for he chemotaxis gene cheb2 in pseudomonas aeruginosa virulence. PLoS Pathog. 2009, 5, e1000540.
78. Pielage, J.F.; Powell, K.R.; Kalman, D.; Engel, J.N. RNAi screen reveals an Abl kinase dependent host cell pathway involved in Pseudomonas aeruginosa internalization. PLoS Pathog. 2008, 4, e1000031.
79. Misselwitz, B.; Dilling, S.; Vonaesch, P.; Sacher, R.; Snijder, B.; Schlumberger, M.; Rout, S.; Stark, M.; von Mering, C.; Pelkmans, L. et al. RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. Mol. Syst. Biol. 2011, 7, 474.
80. Thornbrough, J.M.; Hundley, T.; Valdivia, R.; Worley, M.J. Human genome-wide RNAi screen for host factors that modulate intracellular Salmonella growth. PLoS One 2012, 7, e38097.
81. Qin, Q.M.; Pei, J.; Ancona, V.; Shaw, B.D.; Ficht, T.A.; de Figueiredo, P. RNAi screen of endoplasmic reticulum-associated host factors reveals a role for IRE1alpha in supporting Brucella replication. PLoS Pathog. 2008, 4, e1000110.
82. Zhou, H.; DeLoid, G.; Browning, E.; Gregory, D.J.; Tan, F.; Bedugnis, A.S.; Imrich, A.; Koziel, H.; Kramnik, I.; Lu, Q. et al. Genome-wide RNAi screen in IFN-gamma-treated human macrophages identifies genes mediating resistance to the intracellular pathogen Francisella tularensis. PLoS One 2012, 7, e31752.
83. Stroschein-Stevenson, S.L.; Foley, E.; O'Farrell, P.H.; Johnson, A.D. Identification of Drosophila gene products required for phagocytosis of Candida albicans. PLoS Biol. 2006, 4, e4.
84. Qin, Q.M.; Luo, J.; Lin, X.; Pei, J.; Li, L.; Ficht, T.A.; de Figueiredo, P. Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. PLoS Pathog. 2011, 7, e1002078.
85. Prudencio, M.; Rodrigues, C.D.; Hannus, M.; Martin, C.; Real, E.; Goncalves, L.A.; Carret, C.; Dorkin, R.; Rohl, I.; Jahn-Hoffmann, K. et al. Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection. PLoS Pathog. 2008, 4, e1000201.
86. Rodrigues, C.D.; Hannus, M.; Prudencio, M.; Martin, C.; Goncalves, L.A.; Portugal, S.; Epiphanio, S.; Akinc, A.; Hadwiger, P.; Jahn-Hofmann, K. et al. Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe 2008, 4, 271-282.
87. Chertemps, T.; Mitri, C.; Perrot, S.; Sautereau, J.; Jacques, J.C.; Thiery, I.; Bourgouin, C.; Rosinski-Chupin, I. Anopheles gambiae PRS1 modulates Plasmodium development at both midgut and salivary gland steps. PLoS One 2010, 5, e11538.
88. Genovesio, A.; Giardini, M.A.; Kwon, Y.J.; de Macedo Dossin, F.; Choi, S.Y.; Kim, N.Y.; Kim, C.; Jung, S.Y.; Schenkman, S.; Almeida, I.C. et al. Visual genome-wide RNAi screening to identify human host factors required for Trypanosoma cruzi infection. PLoS One 2011, 6, e19733.
89. Nde, P.N.; Simmons, K.J.; Kleshchenko, Y.Y.; Pratap, S.; Lima, M.F.; Villalta, F. Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection. Infect. Immun. 2006, 74, 1643-1648.
90. Simmons, K.J.; Nde, P.N.; Kleshchenko, Y.Y.; Lima, M.F.; Villalta, F. Stable RNA interference f host thrombospondin-1 blocks Trypanosoma cruzi infection. FEBS Lett. 2006, 580, 2365-2370.
91. Claser, C.; Curcio, M.; de Mello, S.M.; Silveira, E.V.; Monteiro, H.P.; Rodrigues, M.M. Silencing cytokeratin 18 gene inhibits intracellular replication of Trypanosoma cruzi in HeLa cells but not binding and invasion of trypanosomes. BMC Cell Biol. 2008, 9, 68.
92. Berkhout, B. A new Houdini act: Multiple routes for HIV-1 escape from rnai-mediated inhibition. Future Microbiol. 2009, 4, 151-154.
93. Leonard, J.N.; Shah, P.S.; Burnett, J.C.; Schaffer, D.V. HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe 2008, 4, 484-494.
94. Ping, Y.H.; Chu, C.Y.; Cao, H.; Jacque, J.M.; Stevenson, M.; Rana, T.M. Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology 2004, 1, 46.
95. Ye, Y.; De Leon, J.; Yokoyama, N.; Naidu, Y.; Camerini, D. DBR1 siRNA inhibition of HIV-1 replication. Retrovirology 2005, 2, 63.
96. Nguyen, D.G.; Wolff, K.C.; Yin, H.; Caldwell, J.S.; Kuhen, K.L. UnPAKing human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J. Virol. 2006, 80, 130-137.
97. Brass, A.L.; Dykxhoorn, D.M.; Benita, Y.; Yan, N.; Engelman, A.; Xavier, R.J.; Lieberman, J.; Elledge, S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008, 319, 921-926.
98. Zhou, H.; Xu, M.; Huang, Q.; Gates, A.T.; Zhang, X.D.; Castle, J.C.; Stec, E.; Ferrer, M.; Strulovici, B.; Hazuda, D.J. et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008, 4, 495-504.
99. Rato, S.; Maia, S.; Brito, P.M.; Resende, L.; Pereira, C.F.; Moita, C.; Freitas, R.P.; Moniz-Pereira, J.; Hacohen, N.; Moita, L.F. et al. Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells. PLoS One 2010, 5, e9276.
100. Eekels, J.J.; Geerts, D.; Jeeninga, R.E.; Berkhout, B. Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res. 2011, 89, 43-53.
101. Espeseth, A.S.; Fishel, R.; Hazuda, D.; Huang, Q.; Xu, M.; Yoder, K.; Zhou, H. siRNA screening of a targeted library of DNA repair factors in HIV infection reveals a role for base excision repair in HIV integration. PLoS One 2011, 6, e17612.
102. Liu, L.; Oliveira, N.M.; Cheney, K.M.; Pade, C.; Dreja, H.; Bergin, A.M.; Borgdorff, V.; Beach, D.H.; Bishop, C.L.; Dittmar, M.T. et al. A whole genome screen for HIV restriction factors. Retrovirology 2011, 8, 94.
103. Eekels, J.J.; Sagnier, S.; Geerts, D.; Jeeninga, R.E.; Biard-Piechaczyk, M.; Berkhout, B. Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors. Virol. J. 2012, 9, 69.
104. Hao, L.; Sakurai, A.; Watanabe, T.; Sorensen, E.; Nidom, C.A.; Newton, M.A.; Ahlquist, P.; Kawaoka, Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008, 454, 890-893.
105. Brass, A.L.; Huang, I.C.; Benita, Y.; John, S.P.; Krishnan, M.N.; Feeley, E.M.; Ryan, B.J.; Weyer, J.L.; van der Weyden, L.; Fikrig, E. et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139, 1243-1254.
106. Shapira, S.D.; Gat-Viks, I.; Shum, B.O.V.; Dricot, A.; de Grace, M.M.; Wu, L.; Gupta, P.B.; Hao, T.; Silver, S.J.; Root, D.E. et al. A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection. Cell 2009, 139, 1255-1267.
107. Karlas, A.; Machuy, N.; Shin, Y.; Pleissner, K.-P.; Artarini, A.; Heuer, D.; Becker, D.; Khalil, H.; Ogilvie, L.A.; Hess, S. et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010, 463, 818-822.
108. Konig, R.; Stertz, S.; Zhou, Y.; Inoue, A.; Hoffmann, H.H.; Bhattacharyya, S.; Alamares, J.G.; Tscherne, D.M.; Ortigoza, M.B.; Liang, Y. et al. Human host factors required for influenza virus replication. Nature 2010, 463, 813-817.
109. Meliopoulos, V.A.; Andersen, L.E.; Brooks, P.; Yan, X.; Bakre, A.; Coleman, J.K.; Tompkins, S.M.; Tripp, R.A. MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One 2012, 7, e37169.
110. Coller, K.E.; Berger, K.L.; Heaton, N.S.; Cooper, J.D.; Yoon, R.; Randall, G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009, 5, e1000702.
111. Panda, D.; Das, A.; Dinh, P.X.; Subramaniam, S.; Nayak, D.; Barrows, N.J.; Pearson, J.L.; Thompson, J.; Kelly, D.L.; Ladunga, I. et al. RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses. Proc. Natl. Acad. Sci. USA 2011, 108, 19036-19041.
112. Kolokoltsov, A.A.; Saeed, M.F.; Freiberg, A.N.; Holbrook, M.R.; Davey, R.A. Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev. Res. 2009, 70, 255-265.
113. Moser, T.S.; Jones, R.G.; Thompson, C.B.; Coyne, C.B.; Cherry, S. A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog. 2010, 6, e1000954.
114. Mercer, J.; Snijder, B.; Sacher, R.; Burkard, C.; Bleck, C.K.; Stahlberg, H.; Pelkmans, L.; Helenius, A. RNAi Screening Reveals Proteasome- and Cullin3-Dependent Stages in Vaccinia Virus Infection. Cell Rep. 2012, 2, 1036-1047.
115. Mukherjee, S.; Hanley, K.A. RNA interference modulates replication of dengue virus in Drosophila melanogaster cells. BMC Microbiol. 2010, 10, 127.
116. Cherry, S.; Doukas, T.; Armknecht, S.; Whelan, S.; Wang, H.; Sarnow, P.; Perrimon, N. Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. Genes Dev. 2005, 19, 445-452.
117. Chong, C.R.; Sullivan, D.J., Jr. New uses for old drugs. Nature 2007, 448, 645-646.
118. Randall, G.; Panis, M.; Cooper, J.D.; Tellinghuisen, T.L.; Sukhodolets, K.E.; Pfeffer, S.; Landthaler, M.; Landgraf, P.; Kan, S.; Lindenbach, B.D. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. USA 2007, 104, 12884-12889.
119. Supekova, L.; Supek, F.; Lee, J.; Chen, S.; Gray, N.; Pezacki, J.P.; Schlapbach, A.; Schultz, P.G. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J. Biol. Chem. 2008, 283, 29-36.
120. Berger, K.L.; Cooper, J.D.; Heaton, N.S.; Yoon, R.; Oakland, T.E.; Jordan, T.X.; Mateu, G.; Grakoui, A.; Randall, G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. USA 2009, 106, 7577-7582.
121. Tai, A.W.; Benita, Y.; Peng, L.F.; Kim, S.S.; Sakamoto, N.; Xavier, R.J.; Chung, R.T. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009, 5, 298-307.
122. Smith, J.A.; White, E.A.; Sowa, M.E.; Powell, M.L.; Ottinger, M.; Harper, J.W.; Howley, P.M. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc. Natl. Acad. Sci. USA 2010, 107, 3752-3757.
123. Coyne, C.B.; Bozym, R.; Morosky, S.A.; Hanna, S.L.; Mukherjee, A.; Tudor, M.; Kim, K.S.; Cherry, S. Comparative RNAi screening reveals host factors involved in enterovirus infection of polarized endothelial monolayers. Cell Host Microbe 2011, 9, 70-82.
124. Krishnan, M.N.; Ng, A.; Sukumaran, B.; Gilfoy, F.D.; Uchil, P.D.; Sultana, H.; Brass, A.L.; Adametz, R.; Tsui, M.; Qian, F. et al. RNA interference screen for human genes associated with West Nile virus infection. Nature 2008, 455, 242-245.
125. Sessions, O.M.; Barrows, N.J.; Souza-Neto, J.A.; Robinson, T.J.; Hershey, C.L.; Rodgers, M.A.; Ramirez, J.L.; Dimopoulos, G.; Yang, P.L.; Pearson, J.L. et al. Discovery of insect and human dengue virus host factors. Nature 2009, 458, 1047-1050.
126. Ang, F.; Wong, A.P.; Ng, M.M.; Chu, J.J. Small interference RNA profiling reveals the essential role of human membrane trafficking genes in mediating the infectious entry of dengue virus. Virol. J. 2010, 7, 24.
127. Boutros, M.; Bras, L.P.; Huber, W. Analysis of cell-based RNAi screens. Genome Biol. 2006, 7, R66.
128. Tolopko, A.N.; Sullivan, J.P.; Erickson, S.D.; Wrobel, D.; Chiang, S.L.; Rudnicki, K.; Rudnicki, S.; Nale, J.; Selfors, L.M.; Greenhouse, D. et al. Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics 2010, 11, 260.
129. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protocols 2008, 4, 44-57.
130. Khatri, P.; Sirota, M.; Butte, A.J. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 2012, 8, e1002375.
131. Viswanathan, G.A.; Seto, J.; Patil, S.; Nudelman, G.; Sealfon, S.C. Getting started in biological pathway construction and analysis. PLoS Comput. Biol. 2008, 4, e16.
132. DiMasi, J.A.; Hansen, R.W.; Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health. Econ. 2003, 22, 151-185.
133. DiMasi, J.A.; Hansen, R.W.; Grabowski, H.G.; Lasagna, L. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics 1995, 7, 152-169.
134. Collins, F.S. Mining for therapeutic gold. Nat. Rev. Drug Discov. 2011, 10, 397.
135. Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R T. et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 185-191.
136. Yarchoan, R.; Broder, S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N. Engl. J. Med. 1987, 316, 557-564.
137. Allison, M. NCATS launches drug repurposing program. Nat. Biotechnol. 2012, 30, 571-572.
138. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D.T.; Austin, C.P. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 2011, 3, 80ps16.
139. Grinnon, S.T.; Miller, K.; Marler, J.R.; Lu, Y.; Stout, A.; Odenkirchen, J.; Kunitz, S. National Institute of Neurological Disorders and Stroke Common Data Element Project approach and methods. Clin. Trials 2012, 9, 322-329.
140. Wishart, D.S.; Knox, C.; Guo, A.C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901-D906.
141. von Eichborn, J.; Murgueitio, M.S.; Dunkel, M.; Koerner, S.; Bourne, P.E.; Preissner, R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011, 39, D1060-D1066.
142. Terrett, N.K.; Bell, A.S.; Brown, D.; Ellis, P. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 1996, 6, 1819-1824.
143. Goldenberg, M.M. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin. Ther. 1998, 20, 1033-1048.
144. Raja, S.G.; Nayak, S.H. Sildenafil: Emerging Cardiovascular Indications. Ann. Thorac. Surg. 2004, 78, 1496-1506.
145. Wallis, R.S.; Jakubiec, W.M.; Kumar, V.; Silvia, A.M.; Paige, D.; Dimitrova, D.; Li, X.; Ladutko, L.; Campbell, S.; Friedland, G. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 2010, 202, 745-751.
146. Huang, T.S.; Kunin, C.M.; Yan, B.S.; Chen, Y.S.; Lee, S.S.; Syu, W., Jr. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J. Antimicrob. Chemother. 2012, 67, 633-637.
147. Ho Sui, S.J.; Lo, R.; Fernandes, A.R.; Caulfield, M.D.; Lerman, J.A.; Xie, L.; Bourne, P.E.; Baillie, D.L.; Brinkman, F.S. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int. J. Antimicrob. Agents 2012, 40, 246-251.
148. Ekins, S.; Williams, A.J.; Krasowski, M.D.; Freundlich, J.S. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today 2011, 16, 298-310.
149. Henriksen, K.; Christiansen, C.; Karsdal, M.A. Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discov. Today 2011, 16, 967-975.
150. Debnath, A.; Parsonage, D.; Andrade, R.M.; He, C.; Cobo, E.R.; Hirata, K.; Chen, S.; Garcia- Rivera, G.; Orozco, E.; Martinez, M.B. et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 2012, 18, 956-960.
151. Kaimal, V.; Bardes, E.E.; Tabar, S.C.; Jegga, A.G.; Aronow, B.J. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res. 2010, 38, W96-W102.
152. Williams, A.J. Public chemical compound databases. Curr. Opin. Drug Discov. Devel. 2008, 11, 393-404.
153. Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L.J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289, 179-186.
154. Beigel, J.; Bray, M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008, 78, 91-102.
155. Dreitlein, W.B.; Maratos, J.; Brocavich, J. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin. Ther. 2001, 23, 327-355.
156. Kandel, R.; Hartshorn, K.L. Novel strategies for prevention and treatment of influenza. Expert Opin. Ther. Targets 2005, 9, 1-22.
157. Beigel, J.H. Antiviral Compounds In the Pipeline to Tackle H1N1 Influenza Infection. Drugs Future 2010, 35, 385-392.
158. Sui, B.; Bamba, D.; Weng, K.; Ung, H.; Chang, S.; Van Dyke, J.; Goldblatt, M.; Duan, R.; Kinch, M.S.; Li, W.-B. The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. Virology 2009, 387, 473-481.
159. Perwitasari, O.; Yan, X.; Johnson, S.; White, C.; Brooks, P.; Tompkins, S.M.; Tripp, R.A. Targeting the Organic Anion Transporter-3 (OAT3) with Probenecid as a Novel Anti-Influenza A Virus Strategy. Antimicrob. Agents Chemother. 2012, doi: 10.1128/AAC.01532-12.
160. Dantzler, W.H.; Evans, K.K.; Wright, S.H. Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules. J. Pharmacol. Exp. Ther. 1995, 272, 663-672.
161. Stamp, L.K.; O'Donnell, J.L.; Chapman, P.T. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J. 2007, 37, 258-266.
162. Hill, G.; Cihlar, T.; Oo, C.; Ho, E.S.; Prior, K.; Wiltshire, H.; Barrett, J.; Liu, B.; Ward, P. The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion-Correlation of in Vivo and in Vitro Studies. Drug Metab. Dispos. 2002, 30, 13-19.
163. Holodniy, M.; Penzak, S.R.; Straight, T.M.; Davey, R.T.; Lee, K.K.; Goetz, M.B.; Raisch, D.W.; Cunningham, F.; Lin, E.T.; Olivo, N. et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob. Agents Chemother. 2008, 52, 3013-3021.
164. Rayner, C.R.; Chanu, P.; Gieschke, R.; Boak, L.M.; Jonsson, E.N. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharmacol. 2008, 48, 935-947.
165. MacNeil, A.; Rollin, P.E. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl. Trop. Dis. 2012, 6, e1546.
166. Huggins, J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad- spectrum antiviral drug. Rev. Infect. Dis. 1989, 11 Suppl 4, S750-761.
167. Dang, C.V. MYC on the path to cancer. Cell 2012, 149, 22-35.
168. Hermeking, H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 2003, 3, 163-175.
169. Toyoshima, M.; Howie, H.L.; Imakura, M.; Walsh, R.M.; Annis, J.E.; Chang, A.N.; Frazier, J.; Chau, B.N.; Loboda, A.; Linsley, P.S. et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl. Acad. Sci. USA 2012, 109, 9545-9550.